https://doi.org/10.4081/itjm.2022.1532
Anemia and iron in internal medicine: an Italian survey and a review on iron intravenous therapy in medical patients
Published: 18 October 2022
Abstract Views: 1615
PDF: 515
HTML: 17
HTML: 17
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
In Italy, Internal Medicine Units hospitalize approximately 1,300,000 patients, often elderly and comorbid. The prevalent diagnoses are respiratory diseases, heart failure, or pneumonia. As a matter of fact, anemia is probably underestimated in the compilation of the official discharge forms (SDO) according to ICD-9 diagnostic codes. We promoted a survey among the Members the Italian Scientific Society of Internal Medicine (FADOI) with the aim to investigate the prevalence of anemia and iron deficiency, over than certain aspects related to the therapeutic management of patients with anemia. Furthermore, we performed a review summarizing current evidence for iron intravenous therapy in these patients. According to the survey, anemia is present in around half of the patients hospitalized in Internal Medicine, and about a quarter of them shows iron metabolism alterations. In the evaluation of iron metabolism, the dosage of ferritin is the most requested exam, whereas transferrin saturation is less considered. By focusing on some categories of patients, the awareness of the usefulness of intravenous iron therapy in patients with heart failure seems to be sufficiently common (76% of physicians), while it seems lower (60%) in the management of patients with chronic kidney disease (CKD) and anemia. Finally, more than 75% of the physicians answered that, in their hospital, there are few outpatients’ offices or diagnostic pathways dedicated to patients with anemia. Anemia due to absolute or functional iron deficiency is particularly prevalent in Internal Medicine inpatients. For this reason, an accurate evaluation of iron profile and an adequate iron therapy is mandatory in these patients. Recent studies show that, in patients with heart failure, intravenous iron therapy is an effective way of improving patients’ health, regardless of the presence of anemia. Similarly, iron therapy results fundamental to optimize erythropoiesis-stimulating agent efficacy in patients with chronic renal failure. In the next future, other therapeutic aspects of intravenous iron therapy will be probably clarified by several interesting ongoing studies focused on these patients.
Italian Minister of Health. Annual report on hospitalization - Year 2018; June 2019.
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211-59.
DOI: https://doi.org/10.1016/S0140-6736(17)32154-2
Fonseca C, Araújo M, Moniz P, et al. Prevalence and prognostic impact of anemia and iron deficiency in patients hospitalized in an internal medicine ward: The PRO-IRON study. Eur J Haematol 2017;99:505-13.
DOI: https://doi.org/10.1111/ejh.12963
Migone De Amicis M, Poggiali E, Motta I, et al. Anemia in elderly hospitalized patients: prevalence and clinical impact. Intern Emerg Med 2015;10:581-6.
DOI: https://doi.org/10.1007/s11739-015-1197-5
Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy: clinical and pathophysiological insights. Int J Hematol 2018;107:16-30.
DOI: https://doi.org/10.1007/s12185-017-2373-3
Cappellini MD, Comin-Colet J, de Francisco A et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol 2017;92:1068-78.
Cancelo-Hidalgo MJ, Castelo-Blanco C, Palacios S, et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin 2013;29:291-303.
DOI: https://doi.org/10.1185/03007995.2012.761599
Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One 2015;10:e0117383.
DOI: https://doi.org/10.1371/journal.pone.0117383
Nikravesh N, Borchard G, Hofmann H, et al. Factors influencing safety and efficacy of intravenous iron-carbohydrate nanomedicines: From production to clinical practice. Nanomedicine 2020;26:102178.
DOI: https://doi.org/10.1016/j.nano.2020.102178
Neiser S, Rentsch D, Dippon U, et al. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose. Biometals 2015;28:615-35.
DOI: https://doi.org/10.1007/s10534-015-9845-9
Maggioni AP, Opasich C, Anand I, et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail 2005;11:91-8.
DOI: https://doi.org/10.1016/j.cardfail.2004.05.004
Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013;368:1210-9.
DOI: https://doi.org/10.1056/NEJMoa1214865
Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013;165:575-82.e3.
DOI: https://doi.org/10.1016/j.ahj.2013.01.017
Hoes MF, Grote Beverborg N, Kijlstra JD, et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail 2018;20:910-9.
DOI: https://doi.org/10.1002/ejhf.1154
Xu W, Barrientos T, Mao L, Rockman HA, Sauve AA, Andrews NC. Lethal cardiomyopathy in mice lacking transferrin receptor in the heart. Cell Rep 2015;13:533-45.
DOI: https://doi.org/10.1016/j.celrep.2015.09.023
Kobak KA, Radwańska M, Dzięgała M, et al. Heart Failure Rev 2019;24:269-77.
DOI: https://doi.org/10.1007/s10741-018-9738-4
van der Wal HH, Grote Beverborg N, Dickstein K, et al. Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. Eur Heart J 2019;40:3616-25.
DOI: https://doi.org/10.1093/eurheartj/ehz680
Maeder MT, Khammy O, dos Remedios C, Kaye DM. Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. J Am Coll Cardiol 2011;58:474-80.
DOI: https://doi.org/10.1016/j.jacc.2011.01.059
Moliner P, Enjuanes C, Tajes M, et al. Association between norepinephrine levels and abnormal iron status in patients with chronic heart failure: is iron deficiency more than a comorbidity? J Am Heart Assoc 2019;8:e010887.
DOI: https://doi.org/10.1161/JAHA.118.010887
Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48.
DOI: https://doi.org/10.1056/NEJMoa0908355
Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657-68.
DOI: https://doi.org/10.1093/eurheartj/ehu385
Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalizations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 2018;20:125-33.
DOI: https://doi.org/10.1002/ejhf.823
Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial [published correction appears in JAMA 2017; 317(23): 2453]. JAMA 2017;317:1958-66.
DOI: https://doi.org/10.1001/jama.2017.5427
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891-975.
DOI: https://doi.org/10.1002/ejhf.592
Lam CSP, Doehner W, Comin-Colet J, IRON CORE Group. Iron deficiency in chronic heart failure: case-based practical guidance. ESC Heart Fail 2018;5:764-71.
DOI: https://doi.org/10.1002/ehf2.12333
Rognoni C, Gerzeli S. Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact. J Comp Eff Res 2019;8:1099-110.
DOI: https://doi.org/10.2217/cer-2019-0074
Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012;23:1631-4.
DOI: https://doi.org/10.1681/ASN.2011111078
Peters HP, Laarakkers CM, Swinkels DW, Wetzels JF. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant 2010;25:848-53.
DOI: https://doi.org/10.1093/ndt/gfp546
Cappellini MD, Comin-Colet J, de Francisco A, et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol 2017;92:1068-78.
DOI: https://doi.org/10.1002/ajh.24820
Locatelli F, Bárány P, Covic A, et al. Kidney disease: improving global outcomes guidelines on anemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013;28:1346-59.
DOI: https://doi.org/10.1093/ndt/gft033
Minutolo R, Locatelli F, Gallieni M, et al. for the REport of COmorbidities in non-Dialysis Renal Disease Population in Italy (RECORD-IT) Study Group. Anemia management in non-dialysis chronic kidney disease (CKD) patients: a multicenter prospective study in renal clinics. Nephrol Dial Transplant 2013;28:3035-45.
DOI: https://doi.org/10.1093/ndt/gft338
Koulouridis I, Alfayez M, Trikalinos TA, et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a meta-regression analysis. Am J Kidney Dis 2013;61:44-56.
DOI: https://doi.org/10.1053/j.ajkd.2012.07.014
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012;2:279-335.
National Collaborating Centre for Chronic Conditions, Royal College of Physicians. Guideline on anemia management in chronic kidney disease 2015. National Institute for Clinical Excellence. Available from: http://www.nice.org.uk/guidance/NG8/evidence
Mikhail A, Brown C, Williams JA, et al. Renal Association Clinical Practice Guideline - anemia of chronic kidney disease. BMC Nephrol 2017;345:1-29.
DOI: https://doi.org/10.1186/s12882-017-0688-1
Macdougall IC, Bock A, Carrera F, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anemia. Nephrol Dial Transplant 2014;29:2075-84.
DOI: https://doi.org/10.1093/ndt/gfu201
Ponikowski P, Filippatos G, Comin Colet J, et al for the FAIR-HF Trial Investigators. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Failure 2015;17:329-39.
DOI: https://doi.org/10.1002/ejhf.229
Toblli JE, Di Gennaro F. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. PLoS One 2015;10:e0125528.
DOI: https://doi.org/10.1371/journal.pone.0125528
Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicenter, double-blind, randomized, controlled trial Lancet. 2020;396:1895-904.
ClinicalTrials.gov. Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity and mortality (FAIR-HF2). Identifier: NCT03036462.
ClinicalTrials.gov. Randomized placebo-controlled trial of FCM as treatment for heart failure with iron deficiency (HEART-FID). Identifier: NCT03037931.
ClinicalTrials.gov. Intravenous iron treatment in patients with heart failure and iron deficiency: IRONMAN (IRONMAN). Identifier: NCT02642562.
How to Cite
Montagnani, A., Frasson, S., Gussoni, G., Dentali, F., Fontanella, A., & Manfellotto, D. (2022). Anemia and iron in internal medicine: an Italian survey and a review on iron intravenous therapy in medical patients. Italian Journal of Medicine, 16(1). https://doi.org/10.4081/itjm.2022.1532
Copyright (c) 2022 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Claudio Giumelli, Azio Reverzani, Riccardo Volpi, Giuseppe Chesi, Heart failure in real world , Italian Journal of Medicine: Vol. 9 No. 4 (2015)
- Mario Visconti, Proton pump inhibitors overuse: only inappropriate prescriptions or further iatrogenic damage? , Italian Journal of Medicine: Vol. 9 No. 3 (2015)
- Fernando Gallucci, Emiliana Marrone, Roberto Nappi, Maurizio Renis, Maria Gabriella Coppola, Tiziana Ciarambino, Daniele D’Ambrosio, Ada Maffettone, Maria D’Avino, CIN CIN for HF Group Researchers, Results of an observational retrospective multicenter study: “Campania INternal medicine - the Clinical INternist for heart failure” , Italian Journal of Medicine: Vol. 17 No. 1 (2023)
You may also start an advanced similarity search for this article.
List of Cited By :
